Colorectal cancer is the third most common type of cancer in both men and women. Despite advancements in treatment options, there remains an urgent need to develop treatments that may improve long-term prognosis for people with metastatic colorectal cancer.
Bevacizumab, when combined with chemotherapy, is a standard treatment for metastatic colorectal cancer. Bevacizumab targets VEGF, which reduces the blood supply to the tumor and stops the tumor acquiring the oxygen and nutrients that it needs to grow.
Researchers are exploring whether targeting PD-1 (an immune checkpoint) and VEGF (a protein that supports tumor blood vessel growth) at the same time may help the immune system find and attack the cancer cells while also slowing down tumor growth.
About the Symbiotic-GI-03 Clinical Trial
Pfizer’s Symbiotic-GI-03 clinical trial is evaluating a study medicine called PF-08634404 in adults with metastatic (stage IV) colorectal cancer who have not received anticancer treatment for metastatic disease and do not have BRAF V600E mutations or MSI-H/dMMR tumors.
The study medicine is an investigational bispecific antibody designed to target both PD-1 and VEGF at the same time. These proteins can play a role in how the cancer grows and how the immune system responds to it.
Participants will receive either the study medicine in combination with chemotherapy, or bevacizumab, in combination with chemotherapy. Participants will have a 50% chance of receiving either study treatment. This is a double-blind study, meaning neither participants nor the study team will know which study treatment is being given.
Bottom line
The Symbiotic-GI-03 clinical trial is evaluating whether an investigational medicine that targets both PD-1 and VEGF may work better than an approved standard treatment, bevacizumab, when combined with chemotherapy for people with metastatic colorectal cancer.
Ask your doctor whether your tumor has been tested for key biomarkers, including RAS, BRAF V600E, and MSI/dMMR, and whether a first-line clinical trials such as Symbiotic-GI-03 may be an option for you.
ClinicalTrials.gov: NCT07222800
[You can also learn more at [www.PfizerStudyforCRC.com]]